IONS
Ionis Pharmaceuticals, Inc.
Price Chart
Latest Quote
$78.45
+1.94 (+2.53%)
Current Price
| Previous Close | $76.52 |
| Open | $76.69 |
| Day High | $79.55 |
| Day Low | $76.26 |
| Volume | 1,640,076 |
Stock Information
| Shares Outstanding | 165.26M |
| Total Debt | $2.61B |
| Cash Equivalents | $1.98B |
| Revenue | $1.06B |
| Net Income | $-326.98M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $12.97B |
| EPS (TTM) | $-2.01 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $13.28B |
| Sales | $1.06B |
| Income | $-326.98M |
| Book/sh | $2.96 |
| Cash/sh | $11.96 |
| Employees | 1K |
Financial Ratios
| Quick Ratio | 2.86 |
| Current Ratio | 4.10 |
| Debt/Eq | 531.05 |
Returns & Margins
| ROA | -7.03% |
| ROE | -67.62% |
| Gross Margin | 10.94% |
| Operating Margin | -47.72% |
| Profit Margin | -30.90% |
Ownership
| Insider Ownership | 0.61% |
| Institutional Ownership | 107.27% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -105.49 |
| PEG | 27.33 |
| P/S | 12.25 |
| P/B | 26.49 |
Analyst Data
| Recommendation | buy |
| Target Price | $105.91 |
Technical Indicators
| SMA20 | $74.82 |
| SMA50 | $74.97 |
| SMA200 | $75.32 |
| RSI | 63.60 |
| ATR | 2.1661 |
| Shares Float | 163.97M |
| Short Float | 13.64% |
| Short Ratio | 9.45 |
| Volatility | 0.37 |
| Rel Volume | 0.91 |
Performance History
| Week | +5.58% |
| Month | +3.14% |
| Quarter | +7.92% |
| 6 Months | -3.55% |
| YTD | -1.53% |
| Year | +97.92% |
| 3 Years | +91.03% |
| 5 Years | +109.32% |
| 10 Years | +280.48% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-25 | $78.46 | 1,640,076 |
| 2026-06-24 | $76.52 | 2,485,200 |
| 2026-06-23 | $75.99 | 1,405,400 |
| 2026-06-22 | $75.89 | 1,956,100 |
| 2026-06-18 | $74.12 | 2,984,400 |
| 2026-06-17 | $74.31 | 1,788,200 |
| 2026-06-16 | $73.09 | 1,801,400 |
| 2026-06-15 | $73.96 | 1,506,300 |
| 2026-06-12 | $73.28 | 1,964,900 |
| 2026-06-11 | $73.82 | 2,234,400 |
| 2026-06-10 | $73.32 | 1,595,700 |
| 2026-06-09 | $74.58 | 1,568,700 |
| 2026-06-08 | $73.54 | 1,620,700 |
| 2026-06-05 | $74.48 | 1,982,000 |
| 2026-06-04 | $75.13 | 1,240,800 |
| 2026-06-03 | $73.82 | 1,303,900 |
| 2026-06-02 | $72.97 | 2,086,200 |
| 2026-06-01 | $75.38 | 1,467,700 |
| 2026-05-29 | $76.50 | 1,675,600 |
| 2026-05-28 | $77.33 | 1,603,000 |
| 2026-05-27 | $76.49 | 1,341,300 |
| 2026-05-26 | $76.07 | 1,279,200 |
About Ionis Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; DAWNZERA for prophylaxis to prevent attacks of hereditary angioedema in adults; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult patients with spinal muscular atrophy (SMA). It also provides QALSODY for the treatment of Amyotrophic Lateral Sclerosis (ALS); TEGSEDI for the treatment of ATTRv-PN in adults; and WAYLIVRA for treatment for FCS and familial partial lipodystrophy. It also develops products under Phase 3 clinical trials, such as Olezarsen for patients with hypertriglyceridemia (SHTG) and cardiovascular disease (CVD); and Zilganerse, a potential treatment for people with genetically confirmed Alexander disease, as well as ION582 which is in Phase 3 clinical trial for the potential treatment of AS, a rare genetic neurological disease. In addition, the company develops Eplontersen to degrade mutant and wild-type TTR mRNA through binding to the TTR mRNA; Pelacarsen to inhibit the production of apolipoprotein(a) in the liver to offer a direct approach for reducing lipoprotein(a); Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus; Sefaxersen to reduce the production of complement factor B and lower activation of the alternative complement pathway; and Ulefnersen to reduce the production of the fused in sarcoma, as well as other mid-stage pipeline investigational medicines. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with GSK, AstraZeneca, Novartis, and Roche, as well as with Metagenomi. The company was incorporated in 1989 and is headquartered in Carlsbad, California.
đ° Latest News
FDA Expands IONS' Tryngolza Label to Treat Severe Hypertriglyceridemia
Zacks âĸ 2026-06-25T17:29:00Z
IONS Stock Jumps 4% After-Hours â Goldman Sachs Lifts Price Target On Tryngolza Approval
Stocktwits âĸ 2026-06-24T23:54:37Z
Ionis, with new FDA nod, hits a âcommercial inflection pointâ
BioPharma Dive âĸ 2026-06-24T16:50:14Z
How Kardigan spun deal leftovers into a $400M IPO
BioPharma Dive âĸ 2026-06-23T10:21:20Z
QURE Was Just the Beginning: 5 Biotech Catalysts Iâm Watching Now
InvestorPlace âĸ 2026-06-19T12:24:56Z
Is lonis Pharmaceuticals, Inc. (IONS) Among the Best Genomics Stocks to Buy According to Analysts?
Insider Monkey âĸ 2026-06-16T12:52:37Z
Intellia Surges; Can Its Gene-Editing Drug Solve The Chronic Treatment Problem?
Investor's Business Daily âĸ 2026-06-15T21:10:35Z
Assessing Ionis Pharmaceuticals (IONS) Valuation After New Olezarsen Data Plans And Bullish Pipeline Updates
Simply Wall St. âĸ 2026-06-06T15:11:26Z
This $5.5 Million Exit Raises Questions After Wave Life Sciences' Rough First Quarter
Motley Fool âĸ 2026-05-31T20:16:27Z
Why Is Ionis Pharmaceuticals (IONS) Up 3.4% Since Last Earnings Report?
Zacks âĸ 2026-05-29T15:30:15Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $15,909,000 | $11,215,000 | $9,133,000 | $14,116,000 |
| Cost Of Revenue | $15,909,000 | $11,215,000 | $9,133,000 | $14,116,000 |
| Total Revenue | $943,711,000 | $705,138,000 | $787,647,000 | $587,367,000 |
| Operating Revenue | $943,711,000 | $705,138,000 | $787,647,000 | $587,367,000 |
| Expenses | ||||
| Interest Expense | $84,282,000 | $84,357,000 | $81,457,000 | $8,122,000 |
| Total Expenses | $1,325,428,000 | $1,180,245,000 | $1,141,377,000 | $997,558,000 |
| Other Income Expense | $92,627,000 | $105,464,000 | $101,222,000 | $160,328,000 |
| Other Non Operating Income Expenses | $-15,358,000 | $1,331,000 | $14,095,000 | $-7,274,000 |
| Net Non Operating Interest Income Expense | $-90,582,000 | $-90,457,000 | $-81,457,000 | $-8,122,000 |
| Total Other Finance Cost | $6,300,000 | $6,100,000 | $5,900,000 | $5,300,000 |
| Interest Expense Non Operating | $84,282,000 | $84,357,000 | $81,457,000 | $8,122,000 |
| Operating Expense | $1,309,519,000 | $1,169,030,000 | $1,132,244,000 | $983,442,000 |
| General And Administrative Expense | $393,900,000 | $267,500,000 | $232,600,000 | $150,300,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-381,387,000 | $-453,897,000 | $-366,286,000 | $-269,722,000 |
| Net Interest Income | $-90,582,000 | $-90,457,000 | $-81,457,000 | $-8,122,000 |
| Normalized Income | $-466,695,150 | $-556,676,271 | $-435,116,330 | $-402,127,580 |
| Net Income From Continuing And Discontinued Operation | $-381,387,000 | $-453,897,000 | $-366,286,000 | $-269,722,000 |
| Total Operating Income As Reported | $-381,684,000 | $-475,081,000 | $-353,730,000 | $-410,191,000 |
| Net Income Common Stockholders | $-381,387,000 | $-453,897,000 | $-366,286,000 | $-269,722,000 |
| Net Income | $-381,387,000 | $-453,897,000 | $-366,286,000 | $-269,722,000 |
| Net Income Including Noncontrolling Interests | $-381,387,000 | $-453,897,000 | $-366,286,000 | $-269,722,000 |
| Net Income Continuous Operations | $-381,387,000 | $-453,897,000 | $-366,286,000 | $-269,722,000 |
| Pretax Income | $-379,601,000 | $-460,068,000 | $-333,965,000 | $-257,985,000 |
| Operating Income | $-381,717,000 | $-475,107,000 | $-353,730,000 | $-410,191,000 |
| Gross Profit | $927,802,000 | $693,923,000 | $778,514,000 | $573,251,000 |
| Special Income Charges | - | - | - | $0 |
| Per Share | ||||
| Diluted EPS | $-2.38 | $-3.04 | $-2.56 | $-1.90 |
| Basic EPS | $-2.38 | $-3.04 | $-2.56 | $-1.90 |
| Other | ||||
| Tax Effect Of Unusual Items | $22,676,850 | $1,353,729 | $18,296,670 | $35,196,420 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-380,610,000 | $-457,854,000 | $-317,137,000 | $-395,360,000 |
| Total Unusual Items | $107,985,000 | $104,133,000 | $87,127,000 | $167,602,000 |
| Total Unusual Items Excluding Goodwill | $107,985,000 | $104,133,000 | $87,127,000 | $167,602,000 |
| Reconciled Depreciation | $22,694,000 | $21,990,000 | $22,498,000 | $22,105,000 |
| EBITDA (Bullshit earnings) | $-272,625,000 | $-353,721,000 | $-230,010,000 | $-227,758,000 |
| EBIT | $-295,319,000 | $-375,711,000 | $-252,508,000 | $-249,863,000 |
| Diluted Average Shares | $160,000,000 | $150,000,000 | $143,000,000 | $142,000,000 |
| Basic Average Shares | $160,000,000 | $150,000,000 | $143,000,000 | $142,000,000 |
| Diluted NI Availto Com Stockholders | $-381,387,000 | $-453,897,000 | $-366,286,000 | $-269,722,000 |
| Tax Provision | $1,786,000 | $-6,171,000 | $32,321,000 | $11,737,000 |
| Gain On Sale Of Security | $107,985,000 | $104,133,000 | $87,127,000 | $167,602,000 |
| Research And Development | $915,619,000 | $901,530,000 | $899,625,000 | $833,147,000 |
| Selling General And Administration | $393,900,000 | $267,500,000 | $232,619,000 | $150,295,000 |
| Other Gand A | $352,000,000 | $230,500,000 | $205,100,000 | $124,400,000 |
| Salaries And Wages | $41,900,000 | $37,000,000 | $27,500,000 | $25,900,000 |
| Minority Interests | - | - | - | $0 |
| Restructuring And Mergern Acquisition | - | - | - | $0 |
| Other Special Charges | - | - | - | - |
Fetched: 2026-06-22
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $489,089,000 | $588,351,000 | $386,686,000 | $572,887,000 |
| Total Assets | $3,523,836,000 | $3,003,675,000 | $2,990,072,000 | $2,533,876,000 |
| Total Non Current Assets | $533,201,000 | $383,385,000 | $348,219,000 | $331,182,000 |
| Other Non Current Assets | $171,604,000 | $127,278,000 | $105,280,000 | $75,344,000 |
| Current Assets | $2,990,635,000 | $2,620,290,000 | $2,641,853,000 | $2,202,694,000 |
| Other Current Assets | $237,092,000 | $217,934,000 | $205,433,000 | $168,254,000 |
| Inventory | $10,048,000 | $12,512,000 | $7,441,000 | $22,033,000 |
| Receivables | $66,059,000 | $92,188,000 | $97,778,000 | $25,538,000 |
| Other Receivables | $66,059,000 | $92,188,000 | $97,778,000 | $25,538,000 |
| Cash Cash Equivalents And Short Term Investments | $2,677,436,000 | $2,297,656,000 | $2,331,201,000 | $1,986,869,000 |
| Cash And Cash Equivalents | $372,260,000 | $242,077,000 | $399,266,000 | $276,472,000 |
| Non Current Prepaid Assets | - | - | - | - |
| Goodwill And Other Intangible Assets | - | - | - | - |
| Other Intangible Assets | - | - | - | - |
| Debt | ||||
| Net Debt | $1,429,869,000 | $1,012,687,000 | $883,398,000 | $913,782,000 |
| Total Debt | $2,064,512,000 | $1,416,569,000 | $1,453,539,000 | $1,369,195,000 |
| Long Term Debt And Capital Lease Obligation | $1,609,826,000 | $1,407,290,000 | $1,400,376,000 | $1,361,660,000 |
| Long Term Debt | $1,347,443,000 | $1,245,485,000 | $1,229,501,000 | $1,182,719,000 |
| Current Debt And Capital Lease Obligation | $454,686,000 | $9,279,000 | $53,163,000 | $7,535,000 |
| Current Debt | $454,686,000 | $9,279,000 | $53,163,000 | $7,535,000 |
| Other Current Borrowings | $454,686,000 | $9,279,000 | $53,163,000 | $7,535,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $3,034,747,000 | $2,415,324,000 | $2,603,386,000 | $1,960,989,000 |
| Total Non Current Liabilities Net Minority Interest | $2,253,180,000 | $2,106,006,000 | $2,155,296,000 | $1,649,428,000 |
| Other Non Current Liabilities | $551,353,000 | $542,212,000 | $513,736,000 | - |
| Non Current Deferred Liabilities | $92,001,000 | $156,504,000 | $241,184,000 | $287,768,000 |
| Current Liabilities | $781,567,000 | $309,318,000 | $448,090,000 | $311,561,000 |
| Current Deferred Liabilities | $73,761,000 | $78,989,000 | $151,128,000 | $90,577,000 |
| Payables And Accrued Expenses | $136,884,000 | $151,436,000 | $176,072,000 | $164,271,000 |
| Payables | $30,795,000 | $42,998,000 | $28,178,000 | $24,170,000 |
| Total Tax Payable | $2,713,000 | $34,000 | $2,151,000 | $6,249,000 |
| Income Tax Payable | $2,713,000 | $34,000 | $2,151,000 | $6,249,000 |
| Accounts Payable | $28,082,000 | $42,964,000 | $26,027,000 | $17,921,000 |
| Other Current Liabilities | - | - | - | - |
| Equity | ||||
| Common Stock Equity | $489,089,000 | $588,351,000 | $386,686,000 | $572,887,000 |
| Total Equity Gross Minority Interest | $489,089,000 | $588,351,000 | $386,686,000 | $572,887,000 |
| Stockholders Equity | $489,089,000 | $588,351,000 | $386,686,000 | $572,887,000 |
| Gains Losses Not Affecting Retained Earnings | $-25,281,000 | $-30,811,000 | $-32,645,000 | $-57,480,000 |
| Other Equity Adjustments | $-25,281,000 | $-30,811,000 | $-32,645,000 | $-57,480,000 |
| Retained Earnings | $-2,631,195,000 | $-2,249,808,000 | $-1,795,911,000 | $-1,429,625,000 |
| Other | ||||
| Ordinary Shares Number | $163,304,875 | $157,908,815 | $144,340,526 | $142,057,736 |
| Share Issued | $163,304,875 | $157,908,815 | $144,340,526 | $142,057,736 |
| Tangible Book Value | $489,089,000 | $588,351,000 | $386,686,000 | $572,887,000 |
| Invested Capital | $2,291,218,000 | $1,843,115,000 | $1,669,350,000 | $1,763,141,000 |
| Working Capital | $2,209,068,000 | $2,310,972,000 | $2,193,763,000 | $1,891,133,000 |
| Capital Lease Obligations | $262,383,000 | $161,805,000 | $170,875,000 | $178,941,000 |
| Total Capitalization | $1,836,532,000 | $1,833,836,000 | $1,616,187,000 | $1,755,606,000 |
| Additional Paid In Capital | $3,145,402,000 | $2,868,812,000 | $2,215,098,000 | $2,059,850,000 |
| Capital Stock | $163,000 | $158,000 | $144,000 | $142,000 |
| Common Stock | $163,000 | $158,000 | $144,000 | $142,000 |
| Non Current Deferred Revenue | $92,001,000 | $156,504,000 | $241,184,000 | $287,768,000 |
| Long Term Capital Lease Obligation | $262,383,000 | $161,805,000 | $170,875,000 | $178,941,000 |
| Current Deferred Revenue | $73,761,000 | $78,989,000 | $151,128,000 | $90,577,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $116,236,000 | $69,614,000 | $67,727,000 | $49,178,000 |
| Current Accrued Expenses | $106,089,000 | $108,438,000 | $147,894,000 | $140,101,000 |
| Net PPE | $361,597,000 | $256,107,000 | $242,939,000 | $255,838,000 |
| Accumulated Depreciation | $-109,080,000 | $-106,316,000 | $-96,759,000 | $-87,716,000 |
| Gross PPE | $470,677,000 | $362,423,000 | $339,698,000 | $343,554,000 |
| Leases | $89,153,000 | $54,375,000 | $28,276,000 | $28,357,000 |
| Other Properties | $238,549,000 | $161,856,000 | $171,896,000 | $181,544,000 |
| Machinery Furniture Equipment | $101,174,000 | $96,395,000 | $89,729,000 | $83,926,000 |
| Buildings And Improvements | $41,801,000 | $41,228,000 | $41,228,000 | $41,158,000 |
| Land And Improvements | $0 | $8,569,000 | $8,569,000 | $8,569,000 |
| Properties | $0 | $0 | $0 | $0 |
| Finished Goods | $1,096,000 | $276,000 | $154,000 | $164,000 |
| Work In Process | $7,913,000 | $6,679,000 | $5,477,000 | $2,109,000 |
| Raw Materials | $1,039,000 | $5,557,000 | $1,810,000 | $19,760,000 |
| Other Short Term Investments | $2,305,176,000 | $2,055,579,000 | $1,931,935,000 | $1,710,397,000 |
Fetched: 2026-06-22
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-325,667,000 | $-551,288,000 | $-335,502,000 | $-294,469,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-268,583,000 | $-500,947,000 | $-307,513,000 | $-274,370,000 |
| Cash Flow From Continuing Operating Activities | $-268,583,000 | $-500,947,000 | $-307,513,000 | $-274,370,000 |
| Operating Gains Losses | $4,059,000 | $13,328,000 | $6,671,000 | $-147,350,000 |
| Investing Activities | ||||
| Capital Expenditure | $-57,084,000 | $-50,341,000 | $-27,989,000 | $-20,099,000 |
| Investing Cash Flow | $-277,776,000 | $-134,027,000 | $-214,127,000 | $-262,636,000 |
| Cash Flow From Continuing Investing Activities | $-277,776,000 | $-134,027,000 | $-214,127,000 | $-262,636,000 |
| Net Other Investing Changes | - | - | $22,000 | $254,083,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $192,604,000 | $522,729,000 | $49,442,000 | $6,373,000 |
| Financing Cash Flow | $675,840,000 | $478,058,000 | $644,082,000 | $-55,295,000 |
| Cash Flow From Continuing Financing Activities | $675,840,000 | $478,058,000 | $644,082,000 | $-55,295,000 |
| Net Other Financing Charges | $-18,949,000 | - | $507,743,000 | $-10,982,000 |
| Net Common Stock Issuance | $192,604,000 | $522,729,000 | $49,442,000 | $6,373,000 |
| Common Stock Issuance | $192,604,000 | $522,729,000 | $49,442,000 | $6,373,000 |
| Repurchase Of Capital Stock | - | - | - | $0 |
| Other | ||||
| Repayment Of Debt | $-267,815,000 | $-44,671,000 | $-488,103,000 | $-50,686,000 |
| Issuance Of Debt | $770,000,000 | $0 | $575,000,000 | $0 |
| Interest Paid Supplemental Data | $10,782,000 | $10,869,000 | $6,512,000 | $2,898,000 |
| End Cash Position | $372,260,000 | $242,077,000 | $399,266,000 | $276,472,000 |
| Beginning Cash Position | $242,077,000 | $399,266,000 | $276,472,000 | $869,191,000 |
| Effect Of Exchange Rate Changes | $702,000 | $-273,000 | $352,000 | $-418,000 |
| Changes In Cash | $129,481,000 | $-156,916,000 | $122,442,000 | $-592,301,000 |
| Net Issuance Payments Of Debt | $502,185,000 | $-44,671,000 | $86,897,000 | $-50,686,000 |
| Net Short Term Debt Issuance | $0 | $-44,504,000 | $-487,943,000 | $0 |
| Short Term Debt Payments | $0 | $-44,504,000 | $-487,943,000 | $0 |
| Net Long Term Debt Issuance | $502,185,000 | $-167,000 | $574,840,000 | $-50,686,000 |
| Long Term Debt Payments | $-267,815,000 | $-167,000 | $-160,000 | $-50,686,000 |
| Long Term Debt Issuance | $770,000,000 | $0 | $575,000,000 | $0 |
| Net Investment Purchase And Sale | $-220,692,000 | $-83,686,000 | $-186,138,000 | $-496,620,000 |
| Sale Of Investment | $1,697,870,000 | $1,769,172,000 | $1,584,676,000 | $989,152,000 |
| Purchase Of Investment | $-1,918,562,000 | $-1,852,858,000 | $-1,770,814,000 | $-1,485,772,000 |
| Net Intangibles Purchase And Sale | $-5,640,000 | $-5,061,000 | $-4,184,000 | $-4,378,000 |
| Purchase Of Intangibles | $-5,640,000 | $-5,061,000 | $-4,184,000 | $-4,378,000 |
| Net PPE Purchase And Sale | $-51,444,000 | $-45,280,000 | $-23,805,000 | $-15,721,000 |
| Purchase Of PPE | $-51,444,000 | $-45,280,000 | $-23,805,000 | $-15,721,000 |
| Change In Working Capital | $-51,215,000 | $-209,390,000 | $-77,260,000 | $7,571,000 |
| Change In Other Working Capital | $-67,052,000 | $-158,936,000 | $9,869,000 | $-65,035,000 |
| Change In Other Current Assets | $-33,212,000 | $-25,857,000 | $-33,763,000 | $-27,235,000 |
| Change In Payables And Accrued Expense | $36,594,000 | $-25,116,000 | $21,162,000 | $58,157,000 |
| Change In Accrued Expense | $51,954,000 | $-41,106,000 | $13,043,000 | $57,063,000 |
| Change In Payable | $-15,360,000 | $15,990,000 | $8,119,000 | $1,094,000 |
| Change In Account Payable | $-15,360,000 | $15,990,000 | $8,119,000 | $1,094,000 |
| Change In Inventory | $-13,674,000 | $-5,071,000 | $-2,469,000 | $5,326,000 |
| Change In Receivables | $26,129,000 | $5,590,000 | $-72,059,000 | $36,358,000 |
| Other Non Cash Items | $27,127,000 | $34,555,000 | $29,940,000 | $5,373,000 |
| Stock Based Compensation | $133,874,000 | $130,200,000 | $105,809,000 | $100,264,000 |
| Amortization Of Securities | $-23,735,000 | $-37,733,000 | $-28,885,000 | $7,389,000 |
| Depreciation Amortization Depletion | $22,694,000 | $21,990,000 | $22,498,000 | $22,105,000 |
| Depreciation And Amortization | $22,694,000 | $21,990,000 | $22,498,000 | $22,105,000 |
| Amortization Cash Flow | $2,439,000 | $2,336,000 | $2,559,000 | $2,415,000 |
| Amortization Of Intangibles | $2,439,000 | $2,336,000 | $2,559,000 | $2,415,000 |
| Depreciation | $20,255,000 | $19,654,000 | $19,939,000 | $19,690,000 |
| Gain Loss On Investment Securities | $-9,280,000 | $2,892,000 | $1,589,000 | $-149,911,000 |
| Gain Loss On Sale Of PPE | $-3,991,000 | $7,404,000 | $16,649,000 | $531,000 |
| Net Income From Continuing Operations | $-381,387,000 | $-453,897,000 | $-366,286,000 | $-269,722,000 |
| Income Tax Paid Supplemental Data | - | - | $48,334,000 | $5,010,000 |
| Proceeds From Stock Option Exercised | - | - | $0 | $0 |
| Common Stock Payments | - | - | - | $0 |
| Deferred Tax | - | - | - | $0 |
| Deferred Income Tax | - | - | - | $0 |
Fetched: 2026-06-22